Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sabine Tacke has a total of 217 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Insights into the Black Box of Intra-Amniotic Infection and Its Impact on the Premature Lung: From Clinical and Preclinical Perspectives

    by Ying Dong, Stefano Rivetti, Arun Lingampally, Sabine Tacke, Baktybek Kojonazarov, Saverio Bellusci, Harald Ehrhardt

    Intra-amniotic infection (IAI) is one major driver for preterm birth and has been demonstrated by clinical studies to exert both beneficial and injurious effects on the premature lung, possibly due to heterogeneity in the microbial type, timing, and severity of IAI. Due to the inaccessibility of the intra-amniotic cavity during pregnancies, preclinical animal models investigating pulmonary consequences of IAI are indispensable to elucidate the pathogenesis of bronchopulmonary dysplasia (BPD). It is postulated that on one hand imbalanced inflammation, orchestrated by lung immune cells such as macrophages, may impact on airway epithelium, vascular endothelium, and interstitial mesenchyme, resulting in abnormal lung development. On the other hand, excessive suppression of inflammation may as well cause pulmonary injury and a certain degree of inflammation is beneficial. So far, effective strategies to prevent and treat BPD are scarce. Therapeutic options targeting single mediators in signaling cascades and mesenchymal stromal cells (MSCs)-based therapies with global regulatory capacities have demonstrated efficacy in preclinical animal models and warrant further validation in patient populations. Ante-, peri- and postnatal exposome analysis and therapeutic investigations using multiple omics will fundamentally dissect the black box of IAI and its effect on the premature lung, contributing to precisely tailored and individualized therapies.


  • Open Access

    Cloning and Functional Characterization of Dog OCT1 and OCT2: Another Step in Exploring Species Differences in Organic Cation Transporters

    by Marleen Julia Meyer, Simon Falk, Sarah Römer, Clarissa Prinzinger, Sabine Tacke, Joachim Geyer, Stefan Simm, Mladen Vassilev Tzvetkov

    OCT1 and OCT2 are polyspecific membrane transporters that are involved in hepatic and renal drug clearance in humans and mice. In this study, we cloned dog OCT1 and OCT2 and compared their function to the human and mouse orthologs. We used liver and kidney RNA to clone dog OCT1 and OCT2. The cloned and the publicly available RNA-Seq sequences differed from the annotated exon-intron structure of OCT1 in the dog genome CanFam3.1. An additional exon between exons 2 and 3 was identified and confirmed by sequencing in six additional dog breeds. Next, dog OCT1 and OCT2 were stably overexpressed in HEK293 cells and the transport kinetics of five drugs were analyzed. We observed strong differences in the transport kinetics between dog and human orthologs. Dog OCT1 transported fenoterol with 12.9-fold higher capacity but 14.3-fold lower affinity (higher KM) than human OCT1. Human OCT1 transported ipratropium with 5.2-fold higher capacity but 8.4-fold lower affinity than dog OCT1. Compared to human OCT2, dog OCT2 showed 10-fold lower transport of fenoterol and butylscopolamine. In conclusion, the functional characterization of dog OCT1 and OCT2 reported here may have implications when using dogs as pre-clinical models as well as for drug therapy in dogs.


  • Characterization of blood–brain barrier integrity in a B-cell-dependent mouse model of multiple sclerosis

    by Luisa Bell, Tobias Koeniger, Sabine Tacke, Stefanie Kuerten

    Recent studies with B-cell-depleting antibodies have demonstrated clinical success in the treatment of multiple sclerosis (MS) patients. While these antibodies efficiently target B cells in the blood, it is unclear how effective they are in the central nervous system (CNS), especially in the context of limited blood–brain barrier (BBB) permeability and the ongoing discussion on the relevance of B-cell aggregate formation in the brains of SP-MS patients. The aim of this study was to evaluate BBB integrity in the context of B-cell-dependent neuroinflammation in a mouse model of MS. C57BL/6 mice were actively immunized with either myelin oligodendrocyte glycoprotein peptide 35-55 to induce T-cell-dependent experimental autoimmune encephalomyelitis (EAE), or with the myelin basic protein–proteolipid protein fusion protein MP4 for additional B-cell dependence. BBB integrity was assessed using Evans Blue or fluorescein isothiocyanate–dextran injection, respectively, in combination with immunofluorescence staining for key components of the BBB. In both EAE models, tracer leakage into the CNS parenchyma was observed indicating BBB leakiness. Yet, intensity and distribution patterns of leakage differed between the two models. There was no difference in the severity of BBB damage comparing acute and chronic MP4-induced EAE, but the formation of B-cell aggregates was associated with local BBB impairment in this model. This study underscores that a leaky BBB is a characteristic feature of EAE, but it also suggests that extent and region specificity of BBB damage differs between individual EAE models that vary in the underlying immunopathology.


  • Schmerztherapie bei kleinen Heimtieren

    by Andrea Gollwitzer, Lukas Grammel, Julia Henke, Sabine Tacke

    Obwohl gerade in den letzten Jahren viele Fortschritte in der Schmerztherapie beim Tier gemacht wurden, gestaltet sich die Schmerztherapie beim kleinen Heimtier schwieriger als bei Hund und Katze. Es besteht jedoch die ethische Verpflichtung, dass auch diese Tiere eine adäquate Schmerztherapie erhalten. Kaum ein Analgetikum ist zum Einsatz beim kleinen Heimtier zugelassen, oft fehlen pharmakologische Untersuchungen und Dosierungen wurden häufig nur empirisch ermittelt. Aufgrund der kleinen Größe der Tiere ist im Vergleich zu Hund und Katze oft eine höhere Dosis pro Kilogramm Körpergewicht notwendig. Auch die Dosierung selbst lässt sich bei den kleinen Tieren nur schwer korrekt durchführen, denn viele Analgetika müssen vor der Applikation verdünnt werden. Zusätzlich bereitet eine häufige Manipulation der kleinen Heimtiere zur Verabreichung von Analgetika den Patienten Stress und dieser kann den Schmerz verstärken. Im vorliegenden Artikel werden die zum Einsatz beim kleinen Heimtier geeigneten Analgetika beschrieben und die Indikationen für die Anwendung der verschiedenen Analgetikatypen erläutert. Ein spezieller Abschnitt widmet sich der Schmerzerkennung, der Algesimetrie, die sich beim kleinen Heimtier deutlich schwieriger gestaltet. In den letzten Jahren wurden sogenannte „Grimace Scales“ entwickelt, anhand derer der Gesichtsausdruck der Tiere beurteilt wird. Although many advances in pain therapy have been made in recent years, pain therapy is more difficult in the small domestic animal than in cats and dogs. However, there is the ethical obligation that these animals also receive adequate pain therapy. An analgesic is rarely authorized for use in small pets, with pharmacological investigations often lacking and dosages frequently only determined empirically. The small size of the animals often requires a higher dose per kilogram bodyweight compared to cats and dogs. The dosage itself is also difficult to apply in small animals, because many analgesics must be diluted before their use. In addition, frequent manipulation of small animals for analgesic administration induces stress in the patient, which can intensify the pain. In the present article, those analgesics suitable for use in the small domestic animal are described and the indications for the use of the various types of analgesics are explained. A specialized section concentrates on pain detection and algesimetry in the small domestic animal. The detection of pain is much more difficult in small domestic animals. In the last few years so-called “grimace scales“ have been developed which are used to assess the facial expression of the animals.


  • Open Access

    Influence of repeated anaesthesia on physiological parameters in male Wistar rats: a telemetric study about isoflurane, ketamine-xylazine and a combination of medetomidine, midazolam and fentanyl

    by Maike Albrecht, Julia Henke, Sabine Tacke, Michael Markert, Brian Guth

    This study evaluated the influence of repeated anaesthesia using isoflurane (ISO, 2–3 Vol%), ketamine-xylazine (KX, 100 mg·kg−1 + 5 mg·kg−1, i.m.) or a combination of medetomidine-midazolam-fentanyl (MMF, 0.15 mg·kg−1 + 2.0 mg·kg−1 + 0.005 mg·kg−1, i.m.) on heart rate (HR), arterial blood pressure (BP), body temperature (BT), duration of anaesthetic intervals and body weight (BW) in Wistar rats. Rats were instrumented with a telemetric system for the measurement of systolic, diastolic and mean arterial pressure (SAP, DAP, MAP), pulse pressure (PP), HR and BT during induction, maintenance and recovery of anaesthesia. Each anaesthesia was performed six times within three weeks. KX was not antagonized, but ISO delivery was terminated 40 minutes after induction and MMF was reversed with atipamezole-flumazenil-naloxone (AFN, 0.75 mg·kg−1 + 0.2 mg·kg−1 + 0.12 mg·kg−1, s.c.). With repeated anaesthesia, ISO showed a decrease of HR and BP. A significant decrease of PP could be observed with repeated anaesthesia using MMF. HR and BP were not affected by repeated KX anaesthesia, but we noted a reduction of sleeping time and BW. Neither MMF nor ISO showed significant differences in the duration of anaesthetic intervals and BW. With KX we observed tissue necrosis at the injection site and surgical tolerance was not achieved in 25% of the anaesthesias performed. HR, BP values, BT, duration of anaesthetic intervals and BW were affected differently by repeated anaesthesia performed with ISO, KX or MMF. ISO produced a reproducible anaesthesia, thereby being suitable for repeated use, but with a decrease of HR and BP throughout the six anaesthesias. The use of ISO in cases where these parameters should be unaffected is therefore not advised. The inability to produce a surgical tolerance, the reduction of sleeping time and BW, as well as the tissue necrosis are significant contraindications for a repeated use of KX. Only mild changes of BP were found with repeated MMF anaesthesia, so it seems suitable for serial use, unless the high BP and the low HR during the surgical plane of anaesthesia are undesirable for a special procedure.


  • Open Access

    Effects of isoflurane, ketamine-xylazine and a combination of medetomidine, midazolam and fentanyl on physiological variables continuously measured by telemetry in Wistar rats

    by Maike Albrecht, Julia Henke, Sabine Tacke, Michael Markert, Brian Guth

    This study investigated effects on cardiovascular parameters during anaesthesia with isoflurane (ISO, 2–3 Vol%), ketamine-xylazine (KX, 100 mg•kg−1 + 5 mg•kg−1) or a combination of medetomidine-midazolam-fentanyl (MMF, 0.15 mg•kg−1 + 2.0 mg•kg−1 + 0.005 mg•kg−1) in rats throughout induction, maintenance and recovery from anaesthesia. Rats were instrumented with a telemetric system for the measurement of systolic, diastolic and mean arterial pressure (SAP, DAP, MAP), pulse pressure (PP), heart rate (HR) and core body temperature (BT). The parameters were continuously measured before, during and after each type of anaesthesia. Forty minutes after induction, ISO delivery was terminated and MMF was antagonized with atipamezole-flumazenil-naloxone (AFN, 0.75 mg•kg−1 + 0.2 mg•kg−1 + 0.12 mg•kg−1) whereas KX was not antagonized.


  • Open Access

    3rd EACTS Meeting on Cardiac and Pulmonary Regeneration Berlin-Brandenburgische Akademie, Berlin, Germany, 14-15 December 2012

    by A. Bader, A. Brodarac, R. Hetzer, A. Kurtz, C. Stamm, H. Baraki, G. Kensah, S. Asch, A. Martens, I. Gruh, et al.

    CD133pos cells are currently evaluated for use in cardiac cell therapy. We hypothesized that they exert their beneficial effects in a paracrine manner and investigated this in a cell culture ischaemia model. Furthermore, we checked whether purified CD133pos cells perform better than non-fractionated mononuclear cells (MNC).

  • Open Access

    Pharmacological postconditioning with sevoflurane after cardiopulmonary resuscitation reduces myocardial dysfunction

    by Patrick Meybohm, Matthias Gruenewald, Martin Albrecht, Christina Müller, Karina Zitta, Nikola Foesel, Moritz Maracke, Sabine Tacke, Jürgen Schrezenmeir, Jens Scholz, et al.

    Introduction: In this study, we sought to examine whether pharmacological postconditioning with sevoflurane (SEVO) is neuro- and cardioprotective in a pig model of cardiopulmonary resuscitation. Methods: Twenty-two pigs were subjected to cardiac arrest. After 8 minutes of ventricular fibrillation and 2 minutes of basic life support, advanced cardiac life support was started. After successful return of spontaneous circulation (N = 16), animals were randomized to either (1) propofol (CONTROL) anesthesia or (2) SEVO anesthesia for 4 hours. Neurological function was assessed 24 hours after return of spontaneous circulation. The effects on myocardial and cerebral damage, especially on inflammation, apoptosis and tissue remodeling, were studied using cellular and molecular approaches. Results: Animals treated with SEVO had lower peak troponin T levels (median [IQR]) (CONTROL vs SEVO = 0.31 pg/mL [0.2 to 0.65] vs 0.14 pg/mL [0.09 to 0.25]; P < 0.05) and improved left ventricular systolic and diastolic function compared to the CONTROL group (P < 0.05). SEVO was associated with a reduction in myocardial IL-1β protein concentrations (0.16 pg/μg total protein [0.14 to 0.17] vs 0.12 pg/μg total protein [0.11 to 0.14]; P < 0.01), a reduction in apoptosis (increased procaspase-3 protein levels (0.94 arbitrary units [0.86 to 1.04] vs 1.18 arbitrary units [1.03 to 1.28]; P < 0.05), increased hypoxia-inducible factor (HIF)-1α protein expression (P < 0.05) and increased activity of matrix metalloproteinase 9 (P < 0.05). SEVO did not, however, affect neurological deficit score or cerebral cellular and molecular pathways. Conclusions: SEVO reduced myocardial damage and dysfunction after cardiopulmonary resuscitation in the early postresuscitation period. The reduction was associated with a reduced rate of myocardial proinflammatory cytokine expression, apoptosis, increased HIF-1α expression and increased activity of matrix metalloproteinase 9. Early administration of SEVO may not, however, improve neurological recovery.


  • Schmerztherapie mit Metamizol

    by J. Henke, W. Erhardt, S. Tacke

    Gegenstand und Ziel: Die vorliegende Arbeit soll den derzeitigen Wissensstand über die pharmakologische und klinische Wirkung von Metamizol bei Hund, Katze Maus und Ratte vorstellen. Metamizol erlebt in den letzten Jahren eine Renaissance, vor allem in der Humanmedizin. Lange Zeit wurde Metamizol als schwaches Analgetikum mit vorwiegend antipyretischer Wirkung eingestuft und die pharmakologische Wirkung war lange Zeit unbekannt. Heute ist wissenschaftlich nachgewiesen, dass zentrale und periphere Wirkmechanismen für die potente analgetische Wirkung von Metamizol verantwortlich sind. Opioiderge Mechanismen und Hemmung der Zyklooxygenasen gelten heute als gesicherte Wirkmechanismen von Metamizol. Metamizol wirkt aber auch antipyretisch, gering antiphlogistisch, spasmolytisch und antikonvulsiv. Die analgetische Wirkung ist mit der von Opioiden vergleichbar. Die hypotensive Nebenwirkung bei intravenöser Injektion lässt sich durch langsame Applikation weitestgehend vermeiden. Eine Agranulozytose wurde bisher in der Veterinärmedizin nicht beobachtet und auch in der Humanmedizin liegt die Inzidenz unter 0,008%. Die Magen-Darm-Trakt-Verträglichkeit von Metamizol ist als gut einzustufen. Schlussfolgerung und klinische Relevanz: Der vorliegende Artikel zeigt, dass Metamizol auch in der Veterinärmedizin potent analgetisch wirkt und die Verträglichkeit als sehr gut zu bewerten ist. Objective: This article presents the current knowledge of pharmacology and clinical effects of Metamizol (Dipyrone) in dogs, cats and rodents. In the last years Metamizol has experienced a revival especially in human medicine. For long times Metamizol was known as a weak analgesic with especially antipyretic effects. The pharmacological effects were unknown for a long time. Today it is proven that central and peripheral effects are responsible for the potent analgesic efficacy of Metamizol. Opioiderg pathways and inhibition of the cyclooxygenases are proved mechanisms for the effects of this drug. Metamizol also shows antipyretic, weak antiphlogistic, spasmolytic and anticonvulsive effects. The analgesic efficacy is comparable to that of opioids. The side-effect of hypotension after intravenous injection can be avoided by slow injection. Agranulocytosis was never seen in veterinary medicine until now and is a side effect with an incidence of only 0.008% in human medicine. The gastro-intestinal tolerance of Metamizol is very good. Conclusion and clinical relevance: This article shows that Metamizol is an analgesic which is also very effective and well tolerated in veterinary patients.